Importantly, as TGF-β inhibitors are mainly targeting the tumor microenvironment, typically with modest direct effect on cancer cell proliferation, they should be used together with standard cytotoxic chemotherapy to efficiently kill these latter cells. This evidence concerns the gene TGFB1 and neoplasm.